Document is current

Any future updates will be listed below

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma

Crossref DOI link: https://doi.org/10.1007/s10147-025-02830-1

Published Online: 2025-07-12

Published Print: 2025-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark